Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab

Aiyin Chen, Thomas N. Hwang, Laura T. Phan, Timothy J. McCulley, Michael K. Yoon

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.

Original languageEnglish (US)
Pages (from-to)432-435
Number of pages4
JournalMiddle East African Journal of Ophthalmology
Issue number4
StatePublished - Oct 2012
Externally publishedYes


  • Benign Reactive Lymphoid Hyperplasia
  • Rituximab
  • Systemic

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab'. Together they form a unique fingerprint.

Cite this